Loading company
First Tracks Biotherapeutics, Inc.
TRAX · Nasdaq · ·
Next earnings: November 11, 2026
$35.97-2.0%Sep 29 close
- 1M
- -14.1%
TRAX · Nasdaq · ·
Next earnings: November 11, 2026
$35.97-2.0%Sep 29 close
First Tracks Biotherapeutics, Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
From the company’s own 8-K filing.
First Tracks Biotherapeutics, Inc. has no earnings call transcript available.
“First Tracks continues to execute against a broad development strategy for our potentially best-in-class CD122 antagonist, ANB033, and anticipates treating patients across four indications in 2027. We believe ANB033 is uniquely positioned to deliver differentiated clinical and biological outcomes across multiple immune-mediated diseases,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator. To learn more, visit www.FirstTracksBio.com or follow us on LinkedIn .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from First Tracks Biotherapeutics, Inc.’s Item 2.02 8-K filed August 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.